Biomarkers for optimal management of heart failure. Cardiorenal syndrome. Veli-Pekka Harjola Helsinki University Central Hospital Helsinki, Finland
|
|
- Richard Bradford
- 5 years ago
- Views:
Transcription
1 Biomarkers for optimal management of heart failure Cardiorenal syndrome Veli-Pekka Harjola Helsinki University Central Hospital Helsinki, Finland
2 Presenter Disclosure Information V-P Harjola The following relationships exist related to this presentation: No relationships to disclose
3 Cardiorenal syndrome introduction pathophysiology role of biomarkers management of HF
4 Cardiorenal syndrome introduction pathophysiology role of biomarkers management of HF
5 Prevalence of renal failure in HF - mild/moderate/severe = GFR 60-90/30-60/<30 Ml/min Any Renal failure Moderate/severe egfr<90 ml/min (%) egfr <60 ml/min(%) Chronic HF Acute HF Smith GL JACC 2006
6 Glomerular filtration rate and risk Death Cardiovascular event Hospitalization Risk (%) > <15 GFR (ml/min/1.73 m²) Go AS et al. NEJM 2004; 351.
7 RIFLE criteria for ARF Mehta Crit Care 2007:11:R31
8 Cardiorenal syndrome introduction pathophysiology role of biomarkers management of HF
9 CRS 1 AHF-ARF House AA et al. Am J Kidney Dis 56:
10 CRS2 CHF-CRF House AA et al. Am J Kidney Dis 56:
11 Cardiorenal syndrome introduction pathophysiology role of biomarkers management of HF
12 Acute kidney injury biomarkers hours Vaidya VS et al. Annu Rev Pharmacol Toxicol 2008;48. Plasma Cystatin C 12 hours
13 Glomerular filtration rate = function (5.5 =TnT) Damman K. Heart Fail Rev 2011
14 Relationship between serum creatinine and estimated GFR: effect of change in serum creatinine 70-year old white male Conversion of Serum creatinine 1mg/dl = 88.4 umol/l
15 Comparison of creatinine and cystatin C as markers of GFR Lassus J. Heart Fail Rev 2011.
16 PRIDE: 1-year mortality vs. quartiles of NT-proBNP and creatinine clearance in AHF The Author Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please
17 FINN-AKVA 1-year mortality risk in AHF & cysc and NT-proBNP % in the first tertile of both biomarkers (n = 77) % % in the third tertile (n = 76) of both markers CystatinC >1.55 mg/l 10 CystatinC mg/l 0 NT-ProBNP >6341pg/ml NT-ProBNP pg/ml NT-ProBNP <2617 pg/ml CystatinC <1.13 mg/l Lassus J. Eur Heart J 2007: 28,
18 Effect on survival of patients with normal crea and elevated cysc both normal 1-yr mortality 12.6% normal crea but elevated cystatin C 1-year mortality 40.4%. Lassus J. Eur Heart J 2007: 28,
19 Glomerular permeabilty Damman K. Heart Fail Rev 2011
20 The early detection of AKI markers of (tubulointerstitial) injury Damman K. Heart Fail Rev 2011
21 The early detection of AKI NGAL neutrophil gelatinase-associated lipocalin expressed in neutrophilial cells and epithelial tissues upregulated in post-ischemic kidney can be measured both in plasma and urine
22 P-NGAL is an early biomarker for AKI in an adult ICU population Cruz DN. Intensive Care Med (2010) 36:
23 Cardiorenal syndrome introduction pathophysiology role of biomarkers management of HF
24 Approach to the patient with CRS 1. Anticipate 2. Optimize HF therapy 3. Evaluate renal structure and function (US) 4. Optimize diuretic dosing 5. Consider renal-specific therapies a. Renal-dose dopamine b. Nesiritide c. Ultrafiltration and/or hemodialysis 6. Investigational therapies a. Hypertonic saline high-dose loop diuretics?? b. Vasopressin antagonists c. Adenosine antagonists (rolofyllin) Liang. Crit Care Med 2008; 36[Suppl.]:S75 S88
25 Management of renal failure Check for hypovolaemia/dehydration Exclude use of nephrotoxic agents, e.g. NSAIDs Withhold aldosterone antagonist If using loop and thiazide diuretic stop thiazide (uneffective when GFR<30) Consider reducing dose of ACEI/ARB Consider ultrafiltration Dickstein K et al. ESC HF Guidelines 2008
26 Diuretic strategies in AHF Furosemide bolus or infusion? high or low dose? Felker G NEJM 2011 March 3
27 Ultrafiltration should be considered to reduce fluid overload in selectedpatients correct hyponatraemia in symptomatic patients refractory to diuretics UNLOAD (Costanza MR JACC 2007) AHF: UF vs diuretics in AHF UF group less HF hospitalisation and unscheduled visits No serum creatinine or mortality differences
28 Vasopressin V2 antagonism vasopressin = ADH anatgonism increased excretion of water without excretion of Na EVEREST trial, AHF tolvaptan vs pla 60 days: mortality, hospitalisations N.S. improvements in day 1 dyspnea, weight P-Na in hyponatraemic patients Konstam MA. JAMA 2007: 12:1319.
29 Pharmacological Management of Cardiorenal Syndrome 2 House AA International Journal of Nephrology 2011
30 HF management and biomarkers of cardiorenal syndrome cardiorenal syndrome common in HF strongly linked to morbidity and mortality old biomarkers and CysC measure function new biomarkers detect injury earlier renal markers currently mostly used for safety not yet any renal-marker guided-therapy no specific kidney-healer either current trials will give insight to new markers in HF management
31 HF management and biomarkers of cardiorenal syndrome Thank you!
32 Thank you!
33 Diuretic resistence High-dose loop diuretic U-Na tubuloglomerular feedback release of adenosine afferent arteriolar constriction GFR proximal tubular Na-reabsorption Decreased circulatory volume RAAS ja SNS distal tubular cell hypertrophy Na-reabsorption Diuretic resistence (despite persisting hypervolemia)
34 Future biomarkers for CRS Cystatin C (Cys C), erythropoietin (EPO), fatty acid binding protein (FABP), interleukin (IL), kidney injury molecule-1 (KIM-1), liver fatty acid binding protein (L- FABP), N-acetyl-β-D-glucosaminidase (NAG), natriuretic peptides (NP). Maisel konsensus
35 NGAL ja Krea päivystyspotilailla AnnIntMed 2008 Nickolas et al
36 Markers of renal function Glomerular filtration rate creatinine estimated CrCl tai GFR Cockcroft-gault MDRD (Urine CrC) Cystatin C
37 Management of heart failure patients with renal dysfunction ON THE OTHER HAND (more nephrological point of view) No absolute level of creatinine which precludes the use of ACEIs/ARBs. if crea >250 μmol/l (~2.5 mg/dl), specialist supervision crea > 500 μmol/l (~5 mg/dl), haemofiltration or dialysis may be needed Dickstein K et al. ESC HF Guidelines 2008
38 introduction pahophysioogy and definition diagnosis of CRS & current biomarkers management in chronic heart failure management in acute heart failure dosing of drugs based on Crea / egfr safety limits for ACEI/ARB, MRAs: spironolacrone increase in S-crea only after decrease in GFR over 50% vrt TnT BNP ; NGAL cysc -> crea KATSO MUISTIINPANOT PROTECR ei toiminut; fluids, hemodynamic optimation in ARF, CRF >RAAS-ihi weight, urine output (ml/h; ml/kg/min), CVP, CO, PCWP cut off rajat
39 Initiation of ACEI/ARB and kidneys some WRF initially halve the dose, if crea μmol/l (~ mg/dl) stop immediately, if even higher Dickstein K et al. ESC HF Guidelines 2008
40 Management of heart failure patients with renal dysfunction thiazide diuretics ineffective when GFR <30 ml/min impaired clearance of many drugs (e.g. digoxin) Dickstein K et al. ESC HF Guidelines 2008
Cardiorenal Syndrome
SOCIEDAD ARGENTINA DE CARDIOLOGIA Cardiorenal Syndrome Joint session ESC-SAC ESC Congress 2012, Munich César A. Belziti Hospital Italiano de Buenos Aires I have no conflicts of interest to declare Cardiorenal
More informationPivotal Role of Renal Function in Acute Heart failure
Pivotal Role of Renal Function in Acute Heart failure Doron Aronson MD, FESC Department of Cardiology RAMBAM Health Care Campus Haifa, Israel Classification and definitions of cardiorenal syndromes CRS
More informationThe Cardiorenal Syndrome in Heart Failure
The Cardiorenal Syndrome in Heart Failure Van N Selby, MD Assistant Professor of Medicine Advanced Heart Failure Program, UCSF October 9, 2015 Disclosures None 1 Cardiorenal Syndrome (CRS) A pathophysiologic
More informationOvercoming the Cardiorenal Syndrome
Overcoming the Cardiorenal Syndrome October 29, 2016 Randall C Starling MD MPH FACC FESC FHFSA FHFA Professor of Medicine Heart & Vascular Institute Cleveland Clinic Lerner College of Medicine Cleveland
More informationTHE KIDNEY IN HYPOTENSIVE STATES. Benita S. Padilla, M.D.
THE KIDNEY IN HYPOTENSIVE STATES Benita S. Padilla, M.D. Objectives To discuss what happens when the kidney encounters low perfusion To discuss new developments and clinical application points in two scenarios
More informationCardio-Renal Syndrome in Acute Heart Failure:
Cardio-Renal Syndrome in Acute Heart Failure: Target for Therapy Marvin A. Konstam, M.D. Research support and/or consulting relevant to this lecture: Merck, Otsuka, Johnson & Johnson; Amgen; Cardiokine
More informationThe Art and Science of Diuretic therapy
The Art and Science of Diuretic therapy Dr. Fayez EL Shaer Associate Professour of cardiology Consultant cardiologist MD, MSc, PhD, CBNC, NBE FESC, ACCP, FASNC,HFA KKUH, KFCC Heart failure: fluid overload
More informationBiomarkers, the Kidney and the Heart: Acute Kidney Injury
Biomarkers, the Kidney and the Heart: Acute Kidney Injury 12th Annual Conference on Biomarkers in Heart Failure and Acute Coronary Syndromes: Diagnosis, Treatment and Devices San Diego May 13, 2016 Ravindra
More informationHeart Failure and Renal Failure. Gerasimos Filippatos, MD, FESC, FHFA President HFA
Heart Failure and Renal Failure Gerasimos Filippatos, MD, FESC, FHFA President HFA Definition Epidemiology Pathophysiology Management (?) Recommendations for NHLBI in cardiorenal interactions related to
More informationHeart Failure and Renal Disease Cardiorenal Syndrome
Advanced Heart Failure: Clinical Challenges Heart Failure and Renal Disease Cardiorenal Syndrome 17 th Apr 2015 Ju-Hee Lee, M.D Cardiovascular Center, Chungbuk National University Hospital Chungbuk National
More informationDoppler ultrasound, see Ultrasonography. Magnetic resonance imaging (MRI), kidney oxygenation assessment 75
Subject Index Acidemia, cardiorenal syndrome type 3 146 Acute Dialysis Quality Initiative (ADQI) acute kidney injury biomarkers, see Acute kidney injury; specific biomarkers cardiorenal syndrome, see specific
More informationMonitoring of Renal Function in Heart Failure
Monitoring of Renal Function in Heart Failure Adriaan A. Voors, cardiologist The Netherlands Disclosures AAV received consultancy fees and/or research grants from: Alere, Bayer, Cardio3Biosciences, Celladon,
More informationCardiorenal Biomarkers and Heart Failure. Nicholas Wettersten, MD April 7 th, 2017
Cardiorenal Biomarkers and Heart Failure Nicholas Wettersten, MD April 7 th, 2017 Disclosures Still none, but looking for some Acute Kidney Injury Biomarkers 547 in 2015 4112 as of March 2017 Case 1 60
More informationDefining and Managing the Cardiorenal Syndrome in Acute Decompensated Heart Failure. Barry M. Massie Professor of Medicine UCSF
Defining and Managing the Cardiorenal Syndrome in Acute Decompensated Heart Failure Barry M. Massie Professor of Medicine UCSF DISCLOSURES Consulting fees: Merck-Novacardia Novartis Bristol Myers Squibb
More informationCardiorenal Syndrome
Cardiorenal Syndrome Peenida Skulratanasak, M.D. Division of Nephrology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University Definition of Cardiorenal syndrome (CRS) Structural
More informationHyponatremia as a Cardiovascular Biomarker
Hyponatremia as a Cardiovascular Biomarker Uri Elkayam, MD Professor of Medicine University of Southern California Keck School of Medicine elkayam@usc.edu Disclosure Research grant from Otsuka for the
More informationState-of-the-Art: Treatment of Renal Dysfunction in Heart Failure. W. H. Wilson Tang, MD Cleveland Clinic, U.S.A.
State-of-the-Art: Treatment of Renal Dysfunction in Heart Failure W. H. Wilson Tang, MD Cleveland Clinic, U.S.A. Heart Failure Exacerbates Renal Insufficiency ADHERE Registry: Prevalence of CKD by egfr
More informationHeart Failure and Cardio-Renal Syndrome 1: Pathophysiology. Biomarkers of Renal Injury and Dysfunction
CRRT 2011 San Diego, CA 22-25 February 2011 Heart Failure and Cardio-Renal Syndrome 1: Pathophysiology Biomarkers of Renal Injury and Dysfunction Dinna Cruz, M.D., M.P.H. Department of Nephrology San Bortolo
More informationMedical Management of Acutely Decompensated Heart Failure. William T. Abraham, MD Director, Division of Cardiovascular Medicine
Medical Management of Acutely Decompensated Heart Failure William T. Abraham, MD Director, Division of Cardiovascular Medicine Orlando, Florida October 7-9, 2011 Goals of Acute Heart Failure Therapy Alleviate
More informationCardiorenal Syndrome: What the Clinician Needs to Know. William T. Abraham, MD Director, Division of Cardiovascular Medicine
Cardiorenal Syndrome: What the Clinician Needs to Know William T. Abraham, MD Director, Division of Cardiovascular Medicine Orlando, Florida October 7-9, 2011 Renal Hemodynamics in Heart Failure Glomerular
More informationCardiorenal Syndrome Prof. Dr. Bülent ALTUN Hacettepe University Faculty of Medicine Department of Internal Medicine Division of Nephrology
Cardiorenal Syndrome Prof. Dr. Bülent ALTUN Hacettepe University Faculty of Medicine Department of Internal Medicine Division of Nephrology Heart and Kidney The kidney yin dominates water, The heart yang
More informationCardiorenal syndrome. Sofie Gevaert. Ghent University Hospital, Belgium
Cardiorenal syndrome Sofie Gevaert Ghent University Hospital, Belgium Disclosures Consultancy Astra Zeneca Boegringer MSD Novartis 68 y old man, ADHF ICMP, ejection fraction 35 %: progressive dyspnea,
More informationAcute Kidney Injury in the ED
+ Acute Kidney Injury in the ED + Dr Eric Clark, MD FRCPC University of Ottawa Canada Canadian Association of Emergency Physicians + Outline 1. Diagnostic challenges 2. ED treatment 3. Contrast induced
More informationCase Presentation. This presentation is the intellectual property of the author. Contact them for permission to reprint and/or distribute.
Worsening Renal Function in Heart Failure Patients Mark Drazner, MD, MSc Clinical Chief of Cardiology Medical Director, CHF/VAD/Transplant James M. Wooten Chair in Cardiology UT Southwestern Medical Center
More informationAcute Kidney Injury in the Hospitalized Patient
Acute Kidney Injury in the Hospitalized Patient Biff F. Palmer, M.D. Professor of Internal Medicine University of Texas Southwestern Medical Center, Dallas Texas Classification of Acute Kidney Injury 1
More informationHow to define the target population?
Heart Failure 2011 22-24 May. Gothenburg, Sweden Mortality or morbidity as target in acute heart failure trials How to define the target population? Marco Metra, Brescia The Burden of Acute HF Acute HF
More informationA08 Using Kidney Biomarkers for AKI 2: Differential Diagnosis, Interventions and Prognosis
A08 Using Kidney Biomarkers for AKI 2: Differential Diagnosis, Interventions and Prognosis Kent Doi, MD, PhD Emergency and Critical Care Medicine, The Univ of Tokyo, Japan Using kidney biomarkers: Key
More informationThe Triple Threat. Cardiac Care in the NT Annual Workshop 2017 is proudly supported by:
The Triple Threat DR KELUM PRIYADARSHANA FRACP CONSULTANT NEPHROLOGIST ROYAL DARWIN HOSPITAL Cardiac Care in the NT Annual Workshop 2017 is proudly supported by: Pathogenesis Diabetes CKD CVD Diabetic
More informationHyponatremia in Heart Failure: why it is important and what should we do about it?
Objectives Hyponatremia in Heart Failure: why it is important and what should we do about it? Pathophysiology of sodium and water retention in heart failure Hyponatremia in heart failure (mechanism and
More informationRenal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF): A Randomized Clinical Trial
Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF): A Randomized Clinical Trial Horng H Chen MD on behalf of the NHLBI Heart Failure Clinical Research Network Background AHF + Renal
More informationRuolo dei Marcatori Bioumorali nello scompenso cardiaco
Ruolo dei Marcatori Bioumorali nello scompenso cardiaco Head Emergency Medicine Sant Andrea Hospital Director Postgraduate School of Emergency Medicine Faculty od Medicine and Psycology Sapienza University
More informationState of the Art: acute heart failure Is it just congestion?
ESC CONGRESS 2017 Barcelona, 26. 30. August 2017 State of the Art: acute heart failure Is it just congestion? S.B. Felix, FESC Klinik für Innere Medizin B Ernst-Moritz-Arndt-Universität Greifswald 1456
More informationRRT in Advanced Heart Failure and Liver Failure When to start and when to stop?
Critical Care Medicine Apollo Hospitals RRT in Advanced Heart Failure and Liver Failure When to start and when to stop? Ramesh Venkataraman, AB (Int. Med), AB (CCM) Senior Consultant, Critical Care Medicine
More informationContrast-Induced Nephropathy: Evidenced Based Prevention
Contrast-Induced Nephropathy: Evidenced Based Prevention Michael J Cowley, MD, FSCAI Nothing to disclose Contrast-Induced Nephropathy (CIN) Definitions New onset or worsening of renal function after contrast
More informationManagement of Acute Heart Failure
Management of Acute Heart Failure Uri Elkayam, MD Professor of Medicine University of Southern California School of Medicine Los Angeles, California elkayam@usc.edu ADHF Treatments Goals.2 Improve symptoms.
More informationAcute heart failure syndromes: clinical challenges. Pathophysiology. ESC Congress August. Paris, France. Marco Metra
ESC Congress 2011 27-31 August. Paris, France. Acute heart failure syndromes: clinical challenges. Pathophysiology Marco Metra Cardiology, Dept. Of experimental and applied medicine. University of Brescia.
More informationCardio Renal Disease. Dr. Rajasekara Chakravarthi Head, Dept of Nephrology CARE Hospitals Hyderabad
Cardio Renal Disease Dr. Rajasekara Chakravarthi Head, Dept of Nephrology CARE Hospitals Hyderabad PREVALENCE OF CVD IS HIGH CAD LVH CHF (CLINICAL) (ECHO) (CLINICAL) GENERAL POPULATION 5-12% 20% 5% CKD
More informationMinimizing the Renal Toxicity of Iodinated Contrast
Minimizing the Renal Toxicity of Iodinated Contrast Peter A. McCullough, MD, MPH, FACC, FACP, FAHA, FCCP Chief Academic and Scientific Officer St. John Providence Health System Detroit, MI USA Outline
More informationAcute renal failure Definition and detection
Acute renal failure Definition and detection Pierre Delanaye, MD, PhD Nephrology, Dialysis, Transplantation CHU Sart Tilman University of Liège BELGIUM Definition Acute Renal Failure Acute Kidney Injury
More informationWORSENING OF RENAL FUNCTION AFTER RAS INHIBITION IN DECOMPENSATED HEART FAILURE: CLINICAL IMPLICATIONS
WORSENING OF RENAL FUNCTION AFTER RAS INHIBITION IN DECOMPENSATED HEART FAILURE: CLINICAL IMPLICATIONS George Bakris, MD, FASH, FAHA, FASN Professor of Medicine Director, Comprehensive Hypertension Center
More informationMedical Management of Acute Heart Failure
Critical Care Medicine and Trauma Medical Management of Acute Heart Failure Mary O. Gray, MD, FAHA Associate Professor of Medicine University of California, San Francisco Staff Cardiologist and Training
More informationState of the Art Treatment - Hyponatremia, Heart Rate, et al
State of the Art Treatment - Hyponatremia, Heart Rate, et al Uri Elkayam, MD Professor of Medicine University of Southern California Keck School of Medicine elkayam@usc.edu Disclosure Research grant from
More information3/30/2010 ACUTE DECOMPENSATED HEART FAILURE. Robert E. Hobbs, MD CLEVELAND CLINIC. Year Patients in US (millions)
ACUTE DECOMPENSATED HEART FAILURE Robert E. Hobbs, MD CLEVELAND CLINIC EPIDEMIOLOGY OF HEART FAILURE Patients in US (millions) 10.0 10 8 550,000 new cases annually 6 4 5 million Americans have HF; likely
More informationDr.Nahid Osman Ahmed 1
1 ILOS By the end of the lecture you should be able to Identify : Functions of the kidney and nephrons Signs and symptoms of AKI Risk factors to AKI Treatment alternatives 2 Acute kidney injury (AKI),
More informationUri Elkayam, MD. Professor of Medicine University of Southern California Keck School of Medicine
Mihai Gheorghiade, MD Memorial Lecture Use of Vasopressin Antagonists for the Management of Hyponatremia and Volume Overload Uri Elkayam, MD Professor of Medicine University of Southern California Keck
More informationTips & tricks on how to treat an acute heart failure patient with low cardiac output and diuretic resistance
Tips & tricks on how to treat an acute heart failure patient with low cardiac output and diuretic resistance J. Parissis Attikon University Hospital, Athens, Greece Disclosures ALARM investigator received
More informationRenal Quiz - June 22, 21001
Renal Quiz - June 22, 21001 1. The molecular weight of calcium is 40 and chloride is 36. How many milligrams of CaCl 2 is required to give 2 meq of calcium? a) 40 b) 72 c) 112 d) 224 2. The extracellular
More informationRecognizing and Treating Patients with the Cardio-Renal Syndrome
Recognizing and Treating Patients with the Cardio-Renal Syndrome Joachim H. Ix, MD, MAS, FASN Professor of Medicine Chief; Division of Nephrology-Hypertension University of California San Diego 1 Conflicts
More informationEditorial Staying in the Pink of Health for Patients with Cardiorenal Anemia Requires a Multidisciplinary Approach
Editorial Staying in the Pink of Health for Patients with Cardiorenal Anemia Requires a Multidisciplinary Approach Anemia and Heart Failure Ragavendra R. Baliga, MD, MBA James B. Young, MD Consulting Editors
More informationUniversity of Groningen. Cardiorenal interaction in heart failure Damman, Kevin
University of Groningen Cardiorenal interaction in heart failure Damman, Kevin IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check
More informationUrinary biomarkers in acute kidney injury. Max Bell MD, PhD Karolinska University Hospital Solna/Karolinska Institutet
Urinary biomarkers in acute kidney injury Max Bell MD, PhD Karolinska University Hospital Solna/Karolinska Institutet Development of AKI-biomarkers Early markers of AKI, do we need them? GFR drop Normal
More informationG. Allen Bryant III, M.D.,F.A.S.N Director Medical Subspecialties LMH Co-Director Renal Services LMH LMPC Chairman of Board
G. Allen Bryant III, M.D.,F.A.S.N Director Medical Subspecialties LMH Co-Director Renal Services LMH LMPC Chairman of Board Presentation Outline/Goals Convince you that having combined LV dysfunction and
More informationAcute Kidney Injury for the General Surgeon
Acute Kidney Injury for the General Surgeon UCSF Postgraduate Course in General Surgery Maui, HI March 20, 2011 Epidemiology & Definition Pathophysiology Clinical Studies Management Summary Hobart W. Harris,
More informationTreating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment
ESC 2012 27Aug - 3Sep, 2012, Munich, Germany Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment Marco Metra, MD, FESC Cardiology University
More informationControversial issues in heart failure. Can we change the outcome of patients with acute heart failure?
Controversial issues in heart failure Can we change the outcome of patients with acute heart failure? Marco Metra, MD, FESC Associateprofessor of Cardiology. University of Brescia The Burden of Acute HF
More informationAcute heart Failure. Critical cardiac care: update Markku S. Nieminen Helsinki, Finland. M S Nieminen, AHF ,ESC Stockholm
Acute heart Failure Critical cardiac care: update 2010 Markku S. Nieminen Helsinki, Finland M S Nieminen, AHF 300810,ESC Stockholm Acute heart Failure Critical cardiac care: update 2010 Markku S. Nieminen
More informationNovel Natriuretic Peptides
Novel Natriuretic Peptides Frank Ruschitzka, MD, FRCP, FESC Professor of Cardiology Director, Heart Failure and Transplantation Clinic University Hospital Zürich, Switzerland Conflict of interest: Aventis,
More informationUpdate on Cardiorenal Syndrome: A Clinical Conundrum
Advances in Peritoneal Dialysis, Vol. 27, 2011 Eric J. Chan, 1 Kevin C. Dellsperger 1 3 Update on Cardiorenal Syndrome: A Clinical Conundrum Our understanding of the cardiorenal syndrome continues to progress.
More informationCase - Acute Renal Failure
Case - Acute Renal Failure 73 yo diabetic F w hx of mild HBP but normal renal function develops infection of R foot. Over 1 week fever, chills, inflammation swelling of her R foot and leg. She takes Motrin
More informationAldosterone Antagonist. Hyd/ISDN*
Μedical management of heart failure: Update 2014 Dr John T Parissis Attikon University Hospital Athens, Greece Disclosures: Received honoraria as consultant or research grants by Orion- Pharma, Servier,
More informationUNDERSTANDING BLOOD TESTS
UNDERSTANDING BLOOD TESTS Parminder Chaggar Cardiology SpR Northern General Hospital Sheffield Conflict of Interest: Nil OVERVIEW Monitoring drug titration Markers of risk Iron deficiency Thyroid disease
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationCystatin C: A New Approach to Improve Medication Dosing
Cystatin C: A New Approach to Improve Medication Dosing Erin Frazee Barreto, PharmD, MSc, FCCM Assistant Professor of Pharmacy and Medicine Kern Scholar, Center for the Science of Health Care Delivery
More informationNGAL, a new markers for acute kidney injury
NGAL, a new markers for acute kidney injury Prof. J. Delanghe, MD, PhD Dept. Clinical Chemistry Ghent University Lecture Feb 8, 2011 Serum creatinine is an inadequate marker for AKI. > 50% of renal
More informationProfessor and Director. Children s Hospital of Richmond
Evaluation of AKI in term and premature infants Timothy E. Bunchman Professor and Director Pediatric Nephrology & Transplantation Children s Hospital of Richmond Virginia Commonwealth Univ. School of Medicine
More informationA patient with acute heart failure and renal impairment ACCA Masterclass 2017
A patient with acute heart failure and renal impairment Dr Sofie Gevaert Mister P. J.M., 67-years-old Cardiac risk factors: Ex-smoker, AHT, Type 2 diabetes, BMI 43, Hyperlipidaemia Medical history: 2009:
More informationVolume Control in. Wafaa El Aroussy,MD Prof of Cardiology Kasr El Aini Faculty of Medicine September 29 th, 2011
Volume Control in Heart Failure Wafaa El Aroussy,MD Prof of Cardiology Kasr El Aini Faculty of Medicine September 29 th, 2011 What is Heart Failure Heart failure is a multisystem disorder which is characterised
More informationUltrafiltration in Decompensated Heart Failure. Description
Subject: Ultrafiltration in Decompensated Heart Failure Page: 1 of 9 Last Review Status/Date: September 2014 Ultrafiltration in Decompensated Heart Failure Description Ultrafiltration is a technique being
More informationCardiorenal and Renocardiac Syndrome
And Renocardiac Syndrome A Vicious Cycle Cardiorenal and Renocardiac Syndrome Type 1 (acute) Acute HF results in acute kidney injury Type 2 Chronic cardiac dysfunction (eg, chronic HF) causes progressive
More informationBiomarkers for the Prevention of Drug Induced AKI (D-AKI)
Biomarkers for the Prevention of Drug Induced AKI (D-AKI) Sandra Kane-Gill, PharmD, MSc, FCCM, FCCP Associate Professor, University of Pittsburgh Critical Care Medication Safety Pharmacist, UPMC OBJECTIVE
More informationΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ. ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας
ΕΘΝΙΚΟ ΚΑΙ ΚΑΠΟΔΙΣΤΡΙΑΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΑΘΗΝΩΝ ΙΑΤΡΙΚΗ ΣΧΟΛΗ Ά ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ Διευθυντής: Καθηγητής Δημήτριος Τούσουλης ΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας
More informationROSE-AHF and Beyond. Gerasimos Filippatos, FESC, FHFA President Heart Failure Association
ROSE-AHF and Beyond Gerasimos Filippatos, FESC, FHFA President Heart Failure Association From: Braunwald s Heart Disease. 9th ed. Philadelphia, Elsevier, 2011 Determinants and forms of worsening renal
More informationObjectives 6/14/2016. Cardiorenal Syndrome: Critical Link Between Heart and Kidney
Cardiorenal Syndrome: Critical Link Between Heart and Kidney Chris M. Bell, ACNP Cardiology Associates of North Mississippi Objectives Review the 5 Subtypes of the Cardiorenal Syndrome (CRS) Discuss the
More informationPravin Manga Division of Cardiology Department of Medicine University of Witwatersrand
Pravin Manga Division of Cardiology Department of Medicine University of Witwatersrand Overview Definition Epidemiology Biomarkers Treatment Clinical Heart Failure: Syndrome in which patients have typical
More informationAkash Ghai MD, FACC February 27, No Disclosures
Akash Ghai MD, FACC February 27, 2015 No Disclosures Epidemiology Lifetime risk is > 20% for American s older than 40 years old. > 650,000 new cases diagnosed each year. Incidence increases with age: 2%
More informationAKI: definitions, detection & pitfalls. Jon Murray
AKI: definitions, detection & pitfalls Jon Murray Previous conventional definition Acute renal failure (ARF) An abrupt and sustained decline in renal excretory function due to a reduction in glomerular
More informationPearls in Acute Heart Failure Management
Pearls in Acute Heart Failure Management Best Practices Juan M. Aranda Jr., M.D. Professor of Medicine Medical Director of Heart Failure/ Transplant Program University of Florida College of Medicine Disclosures:
More informationAKI Risk Assessment, Prevention & Early Detection. Dr Lui G Forni Worthing Hospital, Brighton & Sussex Medical School
AKI Risk Assessment, Prevention & Early Detection Dr Lui G Forni Worthing Hospital, Brighton & Sussex Medical School Risk Assessment Prevention Early Detection I won t tell you how many In slides 25 I
More informationE.Ritz Heidelberg (Germany)
Predictive capacity of renal function in cardiovascular disease E.Ritz Heidelberg (Germany) If a cure is not achieved, the kidneys will pass on the disease to the heart Huang Ti Nei Ching Su Wen The Yellow
More informationOptimal Use of Iodinated Contrast Media In Oncology Patients. Focus on CI-AKI & cancer patient management
Optimal Use of Iodinated Contrast Media In Oncology Patients Focus on CI-AKI & cancer patient management Dr. Saritha Nair Manager-Medical Affairs-India & South Asia GE Healthcare Context Cancer patients
More informationQUICK REFERENCE FOR HEALTHCARE PROVIDERS
KEY MESSAGES 1 SCREENING CRITERIA Screen: Patients with DM and/or hypertension at least yearly. Consider screening patients with: Age >65 years old Family history of stage 5 CKD or hereditary kidney disease
More informationΒιοδείκτες στην καρδιακή ανεπάρκεια διαγνωστικά και θεραπευτικά δεδομένα. Χριστίνα Χρυσοχόου Επιμ Α Α Παν. Καρδιολογικής Κλινικής, ΙΓΝΑ
Βιοδείκτες στην καρδιακή ανεπάρκεια διαγνωστικά και θεραπευτικά δεδομένα Χριστίνα Χρυσοχόου Επιμ Α Α Παν. Καρδιολογικής Κλινικής, ΙΓΝΑ Παθοφυσιολογία καρδιακής ανεπάρκειας Kaye and Krum Nature Reviews
More informationdecline in kidney function within 90 days Drug treatment: NAC NCT IV UK Recruiting (6/2012) NAC Coronary angiography in healthy
Identifier Phase Location Status (estimated 2x2 factorial design NCT01467466 III USA Not yet recruiting (4/2015) NAC vs. placebo and Intervention Setting Kidney outcome measures Estimated Coronary and
More informationBiomarkers of renal diseases. By Dr. Gouse Mohiddin Shaik
By Dr. Gouse Mohiddin Shaik Introduction Renal system performs several functions Excretory Waste products like urea, creatinine, drug, toxins clearance Regulatory Water, electrolyte and acid base balance
More informationUnderstanding the Cardio-Renal Syndromes
Understanding the Cardio-Renal Syndromes The Cardio-Renal axis: an underestimated player in cardiovascular diseases ESC Congress Munich 27/08/2012 Alberto Palazzuoli Department of Internal Medicine Cardiology
More informationNGAL. Changing the diagnosis of acute kidney injury. Key abstracts
NGAL Changing the diagnosis of acute kidney injury Key abstracts Review Neutrophil gelatinase-associated lipocalin: a troponin-like biomarker for human acute kidney injury. Devarajan P. Nephrology (Carlton).
More informationAcute Kidney Injury. APSN JSN CME for Nephrology Trainees May Professor Robert Walker
Acute Kidney Injury APSN JSN CME for Nephrology Trainees May 2017 Professor Robert Walker Kidney International (2017) 91, 1033 1046; http://dx.doi.org/10.1016/ j.kint.2016.09.051 Case for discussion 55year
More informationReview Article Therapeutic Options for the Management of the Cardiorenal Syndrome
SAGE-Hindawi Access to Research International Journal of Nephrology Volume 2011, Article ID 194910, 10 pages doi:10.4061/2011/194910 Review Article Therapeutic Options for the Management of the Cardiorenal
More informationACUTE KIDNEY INJURY. Stuart Linas U. Colorado SOM
ACUTE KIDNEY INJURY Stuart Linas U. Colorado SOM Marked increases in incidence of dialysis-requiring AKI in last decade JASN 24 37 2013 Question 1 Of patients who recover from an episode of AKI, what percentage
More informationHeart failure: what should be changed? Prof. Gerasimos Filippatos Attikon University Hospital
Heart failure: what should be changed? Prof. Gerasimos Filippatos Attikon University Hospital Disclosures Chair or Committee Member of trials or registries sponsored by Novartis, Bayer, Cardiorentis, Servier
More informationENDPOINTS FOR AKI STUDIES
ENDPOINTS FOR AKI STUDIES Raymond Vanholder, University Hospital, Ghent, Belgium SUMMARY! AKI as an endpoint! Endpoints for studies in AKI 2 AKI AS AN ENDPOINT BEFORE RIFLE THE LIST OF DEFINITIONS WAS
More informationBeneficial Role of Tolvaptan in the Control of Body Fluids Without Reductions in Residual Renal Function in Patients Undergoing Peritoneal Dialysis
Advances in Peritoneal Dialysis, Vol. 29, 2013 Takefumi Mori, 1,2,3 Ikuko Oba, 1 Kenji Koizumi, 1 Mayumi Kodama, 1 Miwako Shimanuki, 1 Mizuho Tanno, 1 Makiko Chida, 1 Mai Saito, 1 Hideyasu Kiyomoto, 1
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Ultrafiltration in Decompensated Heart Failure Page 1 of 9 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Ultrafiltration in Decompensated Heart Failure Professional
More informationPractical Points in Cardiorenal Syndrome
Practical Points in Cardiorenal Syndrome Vichai Senthong, MD. Cardiovascular Unit, Faculty of Medicine Khon Kaen university HFCT Annual Scientific Meeting June 16, 2017, Eastin Grand Sathorn Hotel, Bangkok
More informationThe clinical value of natriuretic peptide testing in heart failure
The clinical value of natriuretic peptide testing in heart failure James L. Januzzi, Jr, MD, FACC, FESC Associate Professor of Medicine Harvard Medical School Roman W. DeSanctis Endowed Clinical Scholar
More informationSUPPLEMENTARY INFORMATION
Supplementary information S1 Studies of the effect of AKI duration on outcomes Study Study group (n) Criteria for AKI Definition of RR Outcomes Uchino et al. All patients admitted to (2010) 1 a university-affiliated
More informationA Guide to Proper Utilization of Biomarkers
A Guide to Proper Utilization of Biomarkers DR. ABEER BAKHSH CONSULTANT CARDIOLOGIST, ADVANCE HEART FAILURE KING FAHD ARMED FORCES HOSPITAL JEDDAH, SAUDI ARABIA Objective: Mechanism of myocardial injury
More informationGlomerular Filtration Rate. Hui Li, PhD, FCACB, DABCC
Glomerular Filtration Rate Hui Li, PhD, FCACB, DABCC Glomerular Filtration Rate (GFR): Amount of blood that is filtered per unit time through glomeruli. It is a measure of the function of kidneys. The
More informationAdvanced Care for Decompensated Heart Failure
Advanced Care for Decompensated Heart Failure Sara Kalantari MD Assistant Professor of Medicine, University of Chicago Advanced Heart Failure, Mechanical Circulatory Support and Cardiac Transplantation
More informationOptimizing CHF Therapy: The Role of Digoxin, Diuretics, and Aldosterone Antagonists
Optimizing CHF Therapy: The Role of Digoxin, Diuretics, and Aldosterone Antagonists Old Drugs for an Old Problem Jay Geoghagan, MD, FACC BHHI Primary Care Symposium February 28, 2014 None. Financial disclosures
More information